| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/11/2023 | 84.94% | Truist Securities | $18 → $14 | Maintains | Buy |
| 09/22/2023 | 45.31% | B of A Securities | $13 → $11 | Maintains | Neutral |
| 07/13/2023 | 177.41% | Baird | $20 → $21 | Maintains | Outperform |
| 06/28/2023 | 164.2% | Baird | → $20 | Reiterates | Outperform → Outperform |
| 06/27/2023 | 164.2% | Baird | $20 → $20 | Reiterates | Outperform → Outperform |
| 05/11/2023 | 137.78% | RBC Capital | $24 → $18 | Maintains | Outperform |
| 05/10/2023 | 124.57% | Canaccord Genuity | $22 → $17 | Maintains | Buy |
| 05/10/2023 | 98.15% | Truist Securities | $17 → $15 | Maintains | Buy |
| 05/10/2023 | 164.2% | Baird | $23 → $20 | Maintains | Outperform |
| 05/10/2023 | 49.27% | Deutsche Bank | $28 → $11.3 | Downgrades | Buy → Hold |
| 05/10/2023 | 45.31% | Stifel | $18 → $11 | Downgrades | Buy → Hold |
| 05/09/2023 | 58.52% | B of A Securities | $21 → $12 | Downgrades | Buy → Neutral |
| 04/13/2023 | 124.57% | Truist Securities | $20 → $17 | Maintains | Buy |
| 03/01/2023 | 203.83% | Baird | $31 → $23 | Maintains | Outperform |
| 11/10/2022 | 296.3% | SVB Leerink | $29 → $30 | Maintains | Outperform |
| 09/20/2022 | 269.88% | Deutsche Bank | $26 → $28 | Maintains | Buy |
| 09/19/2022 | 269.88% | Truist Securities | $26 → $28 | Maintains | Buy |
| 08/10/2022 | 283.09% | RBC Capital | $26 → $29 | Maintains | Outperform |
| 08/10/2022 | 283.09% | SVB Leerink | $24 → $29 | Maintains | Outperform |
| 07/14/2022 | 217.04% | Truist Securities | $20 → $24 | Maintains | Buy |
| 03/08/2022 | 243.46% | RBC Capital | $31 → $26 | Maintains | Outperform |
| 03/02/2022 | 217.04% | SVB Leerink | $32 → $24 | Maintains | Outperform |
| 02/18/2022 | 322.72% | SVB Leerink | $35 → $32 | Maintains | Outperform |
| 11/05/2021 | 362.35% | SVB Leerink | $30 → $35 | Maintains | Outperform |
| 09/27/2021 | 296.3% | SVB Leerink | → $30 | Initiates Coverage On | → Outperform |
| 07/14/2021 | 375.56% | Baird | → $36 | Upgrades | Neutral → Outperform |
| 04/14/2021 | 362.35% | Baird | → $35 | Downgrades | Outperform → Neutral |
| 03/18/2021 | 534.08% | Truist Securities | → $48 | Initiates Coverage On | → Buy |
| 01/26/2021 | 507.66% | B of A Securities | → $46 | Initiates Coverage On | → Buy |
| 12/10/2020 | 547.29% | UBS | → $49 | Initiates Coverage On | → Buy |
| 12/02/2020 | 415.19% | Canaccord Genuity | $36 → $39 | Maintains | Buy |
| 12/02/2020 | 421.8% | SVB Leerink | $32.5 → $39.5 | Maintains | Outperform |
| 11/19/2020 | 375.56% | Canaccord Genuity | $34 → $36 | Maintains | Buy |
| 11/17/2020 | 362.35% | Baird | → $35 | Initiates Coverage On | → Outperform |
| 11/05/2020 | 349.14% | Canaccord Genuity | $31 → $34 | Maintains | Buy |
| 11/05/2020 | 329.33% | SVB Leerink | $23.5 → $32.5 | Maintains | Outperform |
| 08/10/2020 | 309.51% | Canaccord Genuity | → $31 | Initiates Coverage On | → Buy |
| 07/06/2020 | 210.44% | SVB Leerink | $21 → $23.5 | Maintains | Outperform |
| 07/01/2020 | 177.41% | SVB Leerink | → $21 | Initiates Coverage On | → Outperform |
| 06/09/2020 | 217.04% | RBC Capital | → $24 | Initiates Coverage On | → Outperform |
| 05/27/2020 | 164.2% | Stifel | $18 → $20 | Maintains | Buy |
| 02/26/2020 | 137.78% | Stifel | $17 → $18 | Maintains | Buy |
| 01/31/2020 | 124.57% | Stifel | → $17 | Initiates Coverage On | → Buy |
| 01/07/2020 | 98.15% | Jefferies | → $15 | Initiates Coverage On | → Buy |
| 12/11/2019 | 71.73% | SVB Leerink | → $13 | Initiates Coverage On | → Outperform |
| 12/10/2019 | 58.52% | Deutsche Bank | → $12 | Initiates Coverage On | → Buy |
What is the target price for AdaptHealth (AHCO)?
The latest price target for AdaptHealth (NASDAQ: AHCO) was reported by Truist Securities on October 11, 2023. The analyst firm set a price target for $14.00 expecting AHCO to rise to within 12 months (a possible 84.94% upside). 15 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for AdaptHealth (AHCO)?
The latest analyst rating for AdaptHealth (NASDAQ: AHCO) was provided by Truist Securities, and AdaptHealth maintained their buy rating.
When is the next analyst rating going to be posted or updated for AdaptHealth (AHCO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AdaptHealth, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AdaptHealth was filed on October 11, 2023 so you should expect the next rating to be made available sometime around October 11, 2024.
Is the Analyst Rating AdaptHealth (AHCO) correct?
While ratings are subjective and will change, the latest AdaptHealth (AHCO) rating was a maintained with a price target of $18.00 to $14.00. The current price AdaptHealth (AHCO) is trading at is $7.57, which is out of the analyst's predicted range.